1. J Med Biochem. 2021 Jan 26;40(1):17-25. doi: 10.5937/jomb0-25295.

Evaluation of serum Nestin and HOTAIR rs12826786 C>T polymorphism as screening 
tools for breast cancer in Egyptian women.

Aglan SA(1), Elsammak M(1), Elsammak O(2), El-Bakoury EA(3), Elsheredy HG(4), 
Ahmed YS(5), Sultan MH(5), Awad AM(1).

Author information:
(1)Alexandria University, Medical Research Institute, Department of Chemical 
Pathology, Egypt.
(2)Alexandria University, Faculty of Medicine, Egypt.
(3)Alexandria University, Medical Research Institute, Department of 
Radio-diagnosis, Egypt.
(4)Alexandria University, Medical Research Institute, Department of Cancer 
Management and Research, Alexandria, Egypt.
(5)Alexandria University, Medical Research Institute, Department of Experimental 
and Clinical Surgery, Alexandria, Egypt.

BACKGROUND: Nestin is a neural stem cell protein that plays an important role in 
cancer stem cells (CSC) development and proliferation. It has been identified as 
a marker for newly formed endothelial cells and was shown to be preferentially 
expressed in basal and myoepithelial cells of the mammary gland. HOTAIR is long 
intergenic non-coding (linRNA) associated with tumorigenesis through promotion 
of epithelial-mesenchymal transition (EMT) and stemness as well. HOTAIR gene 
contains a functioning single nucleotide polymorphic site rs12826786 C>T that 
has been associated with several cancer types.
METHODS: We evaluated serum Nestin and the HOTAIR rs12826786 C>T polymorphism in 
healthy Egyptian women and those with breast cancer as a possible screening tool 
to identify patients with breast cancer. Also, we tested the possible 
association of the two markers with each other and the aggressiveness of the 
disease.
RESULTS: Patients with breast cancer had a median (Min-Max) of serum Nestin 31.3 
(6.7-167.3 pg/mL), while control subjects had a median (Min-Max) of serum Nestin 
42.3 (25.7-315.95) pg/mL. The best cut-off value for serum Nestin to 
differentiate normal subjects and patients with breast cancer was 39.9 pg/mL. 
This cut-off value had a diagnostic sensitivity of 84.8% and specificity of 
65.1%. There was a significant difference in the distribution of different 
alleles in patients with breast cancer than normal subjects (P=0.039 Exact 
Fisher test). The breast cancer patients group had 23.9% CC, 52.1% CT, and 23.9% 
TT genotypes, respectively, while the control group had 46.9% CC, 42.8% CT, and 
10.2% TT, respectively.
CONCLUSIONS: A significantly low serum Nestin below 39.9 pg/mL and a higher 
percentage of the T/T homozygous variant allele of HOTAIR rs12826786 C>T were 
found in Egyptian patients with breast cancer. We suggest that the reported 
cut-off value of serum Nestin and the presence of C/T polymorphism can be used 
to assess the risk of females for developing breast cancer and might be of 
potential benefit in screening the disease. Larger studies in different ethnic 
groups are needed to confirm our findings.

Publisher: UVOD: Nestin je protein neuronskih matičnih ćelija koji ima važnu 
ulogu u razvoju i proliferaciji matičnih ćelija raka (CSC). Identifikovan je kao 
marker za novoformirane endotelne ćelije, a pokazalo se da je preferencijalno 
izražen u bazalnim i mioepitelnim ćelijama mlečne žlezde. HOTAIR je dugo 
intergensko nekodiranje (linRNA) povezano sa genezom tumora kroz promociju 
epitelno-mezenhimske tranzicije (EMT) kao i karakteristikama matičnih ćelija. 
HOTAIR gen ima jedno funkcionalno nukleotidno polimorfno mesto rs12826786 C > T 
koje je povezano sa nekoliko tipova raka.
METODE: Izvršena je evaluacija serumskog Nestina i HOTAIR rs12826786 C>T 
polimorfizma kod zdravih žena u Egiptu, kao i onih sa karcinomom dojke, kao 
mogućeg skrining alata za identifikaciju pacijenata sa karcinomom dojke. Takođe, 
testirali smo moguću povezanost između ova dva markera i agresivnosti bolesti.
REZULTATI: Pacijentkinje sa karcinomom dojke su imale srednju vrednost 
(Min-Maks) seruma Nestina 31,3 (6,7-167,3 pg/mL), dok su kontrolne ispitanice 
imale srednju vrednost (Min-Maks) seruma Nestina 42,3 (25,7-315,95 pg/mL). 
Najbolja granična vrednost Nestina u serumu koja je ukazivala na razliku između 
zdravih ispitanica i pacijentkinja sa karcinomom dojke bila je 39,9 pg/mL. Ova 
granična vrednost imala je dijagnostičku osetljivost od 84,8% i specifičnost od 
65,1%. Bilo je značajne razlike u distribuciji različitih alela kod 
pacijentkinja sa karcinomom dojke nego kod zdravih ispitanica (P=0,039 Fišerov 
test tačne verovatnoće). Grupa bolesnica sa karcinomom dojke imala je 23,9% CC, 
52,1% CT i 23,9% TT genotipa, dok je kontrolna grupa imala 46,9% CC, 42,8% CT i 
10,2% TT respektivno.
ZAKLJUČAK: Kod egipatskih pacijentkinja koje su imale karcinom dojke otkriven je 
značajno nizak serumski Nestin, ispod 39,9 pg/mL, i veći procenat alela 
homozigotne varijante T/T HOTAIR rs12826786 C>T. Predlažemo da se prijavljena 
granična vrednost Nestina u serumu i prisustvo C/T polimorfizma koristi za 
procenu rizika kod žena za razvoj raka dojke, a može biti i od koristi u 
skriningu bolesti. Potrebne su obimnije studije u različitim etničkim grupama da 
bi se naši nalazi potvrdili.

2021 Sarah A. Aglan, Mohamed Elsammak, Omar Elsammak, Eman A. El-Bakoury, Heba 
G. Elsheredy, Yasser S. Ahmed, Mohamed H. Sultan, Ahmed M. Awad, published by 
CEON/CEES.

DOI: 10.5937/jomb0-25295
PMCID: PMC7857851
PMID: 33584136

Conflict of interest statement: Conflict of Interest: The authors stated that 
they have no conflicts of interest regarding the publication of this article.